FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Murcray Scott 		2. Issuer Name and Ticker or Trading Symbol

VNUS MEDICAL TECHNOLOGIES INC [ VNUS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Principal Accounting Officer
(Last)          (First)          (Middle)

C/O VNUS MEDICAL TECHNOLOGIES, INC., 5799 FONTANOSO WAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/17/2009
(Street)

SAN JOSE, CA 95138
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/17/2009     D    780   (1) D $29.00   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units     (2) 6/17/2009     D  (3)       7000   (3)     (4)   (4) Common Stock   7000   $0.00   0   D    
Restricted Stock Units     (2) 6/17/2009     D  (3)       2250   (3)     (5)   (5) Common Stock   2250   $0.00   0   D    
Restricted Stock Units     (2) 6/17/2009     D  (3)       2625   (3)     (6)   (6) Common Stock   2625   $0.00   0   D    
Employee Stock Options (right to buy)   $13.78   6/17/2009     D  (7)       3126   (7)     (8) 7/2/2017   Common Stock   3126   $0.00   0   D    

Explanation of Responses:
( 1)  Represents restricted stock units that vested in full and were canceled pursuant to the Agreement and Plan of Merger, dated as of May 7, 2009, by and among Covidien Group S.a.r.l., VNUS Medical Technologies, Inc. (the "Issuer") and Covidien Delaware Corp. (the "Merger"). At the effective time of the Merger, these restricted stock units vested in full and were canceled in exchange for the right to receive a cash payment of $29.00 for each share into which the vested restricted stock units would otherwise be convertible (without interest and less any applicable withholding taxes).
( 2)  Prior to the effective time of the Merger, the Reporting Person was entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
( 3)  These restricted stock units vested in full and were canceled at the effective time of the Merger in exchange for the right to receive a cash payment of $29.00 for each share into which the vested restricted stock units would otherwise be convertible (without interest and less any applicable withholding taxes).
( 4)  Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from July 1, 2008.
( 5)  Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from November 1, 2007.
( 6)  Prior to the effective time of the Merger, the restricted stock units were scheduled to vest in four (4) successive and equal annual installments measured from July 2, 2007.
( 7)  These options were canceled at the effective time of the Merger in exchange for a cash payment of $47,577.72, representing the number of shares of Issuer's common stock underlying such options multiplied by $29.00, less the aggregate exercise price of the options.
( 8)  Prior to the effective time of the Merger, the shares subject to these options were scheduled to vest over four years, with 25% of the shares vesting on July 2, 2008, and 1/36th of the shares vesting monthly thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Murcray Scott
C/O VNUS MEDICAL TECHNOLOGIES, INC.
5799 FONTANOSO WAY
SAN JOSE, CA 95138

Principal Accounting Officer

Signatures
/s/ Cindee Van Vleck, Attorney-in-Fact for Scott Murcray 6/17/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Vnus Medical Technologies (MM) (NASDAQ:VNUS)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Vnus Medical Technologies (MM).
Vnus Medical Technologies (MM) (NASDAQ:VNUS)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Vnus Medical Technologies (MM).